Sector Update: Healthcare Shares Mixed Pre-Market; Bristol-Myers Study on Yervoy Misses Endpoint

By
A A A

Healthcare stocks:

JNJ: +0.11%

PFE: -0.07%


ABT: 0

MRK: -0.02%

AMGN: flat

Healthcare shares are flat to lower in pre-market. Bristol-Myers Squibb Co. ( BMY ) reported results from the Phase 3 randomized, double-blind clinical trial comparing Yervoy to placebo following radiation in patients with advanced metastatic castration-resistant prostate cancer.

The company said the study's primary endpoint of overall survival "did not reach statistical significance." However, anti-tumor activity was observed across some efficacy endpoints, including progression free-survival. BMY is flat at $43.26 in pre-market trade.

And Vertex Pharmaceuticals ( VRTX ) will replace Advanced Micro Devices Inc. ( AMD ) in the S&P 500. VRTX is up 2.4% at $81.74 in pre-market trade. AMD is down 1.6% at $3.76.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


This article appears in: Investing , Commodities

Referenced Stocks: AMD , BMY , VRTX

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

Avatars of the Luxe Life
Avatars of the Luxe Life            

Stocks

Referenced

Most Active by Volume

72,707,992
  • $6.7462 ▲ 11.32%
50,510,563
  • $6.78 ▲ 1.19%
49,759,080
  • $17.415 ▲ 0.90%
43,510,852
  • $7.785 ▲ 1.90%
39,737,182
  • $111.83 ▲ 2.21%
36,196,573
  • $44.945 ▲ 9.20%
35,743,272
  • $7.09 ▲ 1.00%
34,024,087
  • $103.78 ▲ 1.94%
As of 12/18/2014, 02:40 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com